Drug Profile
Research programme: antibody diagnostics and therapeutics - Immunomedics
Alternative Names: (14)-3s; (19)-3s; (E1)-3s; (M1)-3s; 20-(74)-(74) antibody; 20-2b; 74-(20)-(20) antibody; Anti-CD19 antibodies; anti-CD20/CD74 antibodies; bsMAb; Ck-20-2b; CK-22-(20)-(20); E1.BB.3z-92MI; MAb-Rap; TF 12; TF 3; TF 4; TF 5; Veltuzumab-interferon-α2b conjugateLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator IBC Pharmaceuticals; Immunomedics
- Developer Immunomedics
- Class Bispecific antibodies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Recombinant fusion proteins; Ribonucleases
- Mechanism of Action Apoprotein stimulants; Glycoprotein modulators; Ionising radiation emitters; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; T lymphocyte stimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Gastric cancer; Lymphoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (Parenteral)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)